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Abstract 
Background and Purpose 
AMPA receptor positive allosteric modulators represent a potential therapeutic strategy to 
improve cognition in people with schizophrenia.  These studies collectively constitute the 
pre-clinical pharmacology data package used to build confidence in the pharmacology of this 
molecule and enable a clinical trial application. 
Experimental Approach 
 [N-[(2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro 1H-inden-2-yl]-2-propanesulfonamide] 
(UoS12258) was profiled in a number of in vitro and in vivo studies to highlight its suitability 
as a novel therapeutic agent. 
Key Results 
We demonstrated that UoS12258 is a selective, positive allosteric modulator of the AMPA 
receptor.  At rat native hetero-oligomeric AMPARs UoS12258 displayed a minimum 
effective concentration of approximately 10 nM in vitro and enhanced AMPAR-mediated 
synaptic transmission at an estimated free brain concentration of approximately 15 nM in 
vivo.  UoS12258 reversed a delay-induced deficit in novel object recognition (NOR) in rats 
  
after both acute and sub-chronic dosing. Sub-chronic dosing reduced the minimum effective 
dose from 0.3 mg/kg to 0.03 mg/kg.  UoS12258 was also effective at improving performance 
in two other cognition models i.e. passive avoidance in scopolamine-impaired rats and water 
maze learning and retention in aged rats.  In side-effect profiling studies, UoS12258 did not 
produce significant changes in the maximal electroshock threshold (MEST) test at doses 
below 10 mg/kg. 
Conclusion and Implications 
We conclude that UoS12258 is a potent and selective AMPAR modulator exhibiting 
cognition enhancing properties in several rat behavioural models superior to other molecules 
which have previously entered clinical evaluation.   
 
 
1. Introduction 
Many lines of evidence support the premise that enhancing AMPAR (α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor) function should be a viable route to treating a 
variety of disorders that are underpinned by a hypoglutamatergic state, such as schizophrenia 
(Goff 2001, Ozawa 1998, Sanacora 2008, Zarate 2008). The AMPA receptor itself is a family 
of tetrameric ionotropic receptors arising from four genes that encode four distinct subunits, 
named GluA1-4, or previously GluR1-4/A-D (Collingridge et al 2009).   This diversity of 
subunits gives rise to heterogeneity of AMPAR composition in native brain states (Benyeto 
2004), further complicated by both the presence of splice variants and post-translational 
editing (Seeburg 2001, Sommer 1990 ).  Two main sub-populations arise from the editing of 
a Ca2+-permeable glutamine residue in the re-entrant M2 loop of the GluA2 subunit to a Ca2+-
impermeable arginine, which renders the edited receptors permeable to just Na+ and K+ 
(Gouaux 2004).  Other than this re-entrant M2 loop, each subunit also comprises three 
transmembrane domains (M1, 3, 4), an intra-cellular C-terminal domain, key for regulation of 
trafficking, as well as an extensive extracellular N-terminal domain containing both the 
glutamate-binding site domain (commonly referred to as the ligand-binding or agonist-
binding domain) and an N-terminal domain (Traynelis 2010).  Functionally active AMPARs 
can be formed from any combination of the GluA subunits, although different combinations 
of different subunits display different biophysical and kinetic properties as well as distinct 
regional distributions and trafficking potential (Herguedas 2016).   Specifically for 
  
distribution, GluA1, GluA2 and GluA3 subunits are found at high levels in the hippocampus, 
basal ganglia, amygdala, lateral septum and cerebellum in rat and macaque, whereas GluA4 
is most highly expressed in the cerebellum (Boutler 1990, Keinanen, 1990, Beneyto 2004). 
Glutamate is the major excitatory neurotransmitter, and AMPA receptors, are responsible for 
mediating the majority of fast, excitatory synaptic transmission, and as such, offer a great 
opportunity for modulation for therapeutic benefit.  Repetitive AMPAR stimulation leads to 
activation of another group of ionotropic glutamate receptors, NMDA receptors, by voltage-
mediated release of magnesium ion block.  This enables greater influx of calcium ions into 
the post synaptic neuron, and onward synaptic transmission and processes required for 
memory deposition and learning, which are further strengthened by increased trafficking of 
AMPA receptors to the membrane (Lynch 2002). 
 
1.1 Glutamate receptors and schizophrenia 
The considerable body of data linking glutamate receptors to schizophrenia comprises both 
empirical observations and genetic associations.  Studies in schizophrenic patients have 
identified various supporting lines of data, including reduced glutamate concentrations in 
cerebro-spinal fluid (Kim 1980), reduced hippocampal glutamate from post mortem studies 
(Harrison 2000), reduced glutamate neurotransmission, reduced carboxypeptidase II (Tsai 
2004) and increased N-acetyl-aspartyl glutamate (endogenous iGluR antagonist) (Jessen 
2013).  Additionally, evidence from immunocytochemical studies on different brain regions 
of patients as well as analysis of mRNA transcript level changes in hippocampal regions of 
schizophrenia brains indicates reductions in AMPAR levels in prefrontal & temporal cortical 
and thalamic regions that are associated with the performance of cognitive tasks (Akbarian 
1995, Wright 2012).  Wider evidence comes from the NMDA receptor, for which it is clear 
that administration of an NMDAR blocker, such as phencyclidine (PCP) or ketamine, is able 
to both amplify the symptoms of schizophrenia in schizophrenic patients (Lahti 1995), and 
also induce a ‘schizophrenia-like’ state including psychosis and disrupted cognition in 
healthy volunteers (Lahti 2001).  These data are more compelling for NMDAR blocking 
agents than for other agents, such as dopamine-releasers such as the amphetamines (Le Pen 
2003).     
 
  
1.2 AMPAR positive modulators 
Given the evidence associating reduced AMPA receptor-mediated neurotransmission with 
various disease states, it is not surprising that considerable effort has been expended in trying 
to identify ways to increase glutamatergic transmission.   Direct activation approaches suffer 
from the loss of spatial and temporal control of activation of endogenous glutamate binding 
and also will run a significant safety and tolerability risk of generating undesirably high 
excitatory signalling levels.  To overcome both of these liabilities, positive allosteric 
modulators have been targeted over the recent decades, such that the glutamate signalling will 
be enhanced if, and only if, both glutamate and positive modulator are bound at the receptor.  
A range of molecules has been reported, from various groups, which have been studied in 
different pre-clinical species as well as clinically.  These molecules have generated 
considerable in vitro data to support their mechanisms of action, and in particular, have been 
shown to be selective for the AMPAR subtype of glutamate receptor over the other iGluR 
and mGluR receptor subtypes (unlike the majority of orthosteric-site binding ligands).  In 
addition to effects directly at the receptor, these molecules have demonstrated potentiation in 
native tissue and hippocampal slice preparations, particularly generating facilitation of 
polysynaptic responses (Arai 1996, Lynch 2002), long-term potentiation, increased BDNF 
levels and activity in a wide range of animal models of learning and memory (Woolley 2009).  
Specifically for models of cognition, molecules have demonstrated improved performance in 
olfactory discrimination, radial arm maze (Staubli et al 1994), conditioned fear (Rogan et al 
1997), water maze performance (Zivkovic et al 1995; Quirk and Nisenbaum 2001), delayed 
non match to sample (Hampson et al 1998), novel object recognition (Lebrun et al 2000), 
passive avoidance (Lebrun 2000, Quirk and Nisenbaum 2001) in rodents and have also 
demonstrated encouraging results in non-human primates (Thompson et al 1995, Buccafusco 
2004, Porrino 2005).   In addition to the behavioural pharmacology understanding, the 
knowledge of the overall structure of the receptor offers the opportunity to exploit structure-
based design opportunities against the extracellular binding domains (Baranovic 2016). 
 
1.3 AMPAR positive modulators – clinical studies 
Although there have been many reports of AMPAR positive allosteric modulators in pre-
clinical studies, relatively few have been progressed beyond Phase I into patient studies.  The 
initial clinical evaluation was driven by the set of CX molecules originating from the 
  
University of California, subsequently as Cortex, from the pioneering work of Gary Lynch.  
These molecules initially demonstrated effects in healthy young (Ingvar et al., 1997) and 
aged volunteers (Lynch et al., 1997), as well as in schizophrenic patients stabilised on the 
atypical antipsychotic drug clozapine (Goff et al 2001), but were subsequently ineffective in a 
later study (Goff et al., 2008).  Studies with later compounds have generated effects in 
attention deficit hyperactivity disorder (ADHD) patients (2006, Weisler 2007).  The second 
major class of the phenethylamine sulphonamides produced two clinical stage molecules 
from Lilly, one of which was reported as negative in a Phase II study of cognition in 
Alzheimer’s disease, as well as molecules from GlaxoSmithKline (Ward 2011, 2010) and 
Pfizer (Shaffer 2015).  
2. Methods 
2.1 Compound 
The chemical structure of UoS12258 is shown in Figure 1. The preparation and preliminary 
characterization of UoS12258 has been described previously (Ward 2010). 
Figure 1 
2.2 Intracellular Ca2+ influx assay 
AMPA receptors: Human Embryonic Kidney (HEK293) sticky cells (293 TAg/hsr-A pCIP4) 
were grown in a Dulbecco’s modified eagle medium nutrient mixture F-12 (DMEM/F-12) 
supplemented with 10 % foetal bovine serum (FBS), 2 mM glutamine, and 1.5 ug/mL 
puromycin in a 5 % CO2 humidified atmosphere at 37 °C. Transient transfection was 
performed according to the lipofectamine 2000 method. Briefly, a sub-confluent T-175 cm2 
flask was washed with PBS to remove serum and 20 mL of optimem were added. Separately, 
in 10 mL optimem, 100 µg DNA were pre-incubated with 300 µL of lipofectamine for 20 
min at room temperature and then added to the flask. After 4 h of incubation at 37 °C 5 % 
CO2, cells were detached with versene and resuspended in the post transfection medium 
(DMEM supplemented by 10 % of dialyzed FBS). The confluent monolayer for the 
functional assay was obtained by seeding 7500cell/well 2 days prior the experiment in 384-
well black with clear bottom, poly-D-lysine coated plates (Greiner). 
The following homomeric AMPAR subtypes were studied: human GluA1 flip isoform 
(hGluA1i), hGluA3i and hGluA4i and rat GluA2i using DNAs (all Q-unedited in TM2 region 
  
to allow Ca2+ permeability) hGRIA1i, 3i and 4i and rGRIA2i. Human GluA2i was studied 
using HEK293-hGR1A2i Q-unedited RC17 cell line that was established in house. 
NMDA receptors: HEK293 sticky cells, grown at 80-95% confluency in 175cm2 T-flask, 
were transduced by addition of 5% NR1A-BacMam / 25% NR2B-BacMam mixture in 15 mL 
of medium containing DMEM/F-12, 10% dialyzed FCS, 0.3 mM MgCl2, 500 µM ketamine 
hydrochloride (non-competitive NMDAR antagonist). Cells were incubated with the 
transduction mixture at 37 °C in 5% CO2 for 24 h. Then, BacMam was washed away with 
PBS, and cells were plated onto poly-D-lysine coated black/clear plates at a density of 20,000 
cells/well, always in presence of 500 µM ketamine hydrochloride. After additional 24 h cells 
were tested in FLIPR assay. 
Kainate receptors: Transient transfection was performed according to the lipofectamine 2000 
method. Briefly, a sub-confluent T-175cm2 flask was washed with PBS to remove serum and 
added by 20 mL of optimem. Separately, in 10 mL optimem, 60 µg pcDNA3.2-human 
GRIK1 (Q/unedited) were pre-incubated with 300 µL of lipofectamine for 20 min at room 
temperature and then added to the flask. After 4 h incubation at 37 °C 5% CO2, cells were 
detached with versene and resuspended in the post transfection medium (DMEM 
supplemented by 10% of dialyzed foetal bovine serum). The confluent monolayer for the 
functional assay was obtained by seeding 7,500 cells/well one day prior the experiment in 
384-well black with clear bottom, poly-D-lysine coated plates. 
Intracellular calcium levels through AMPA receptors were measured. Buffer comprised 
(mM): 20 HEPES, 145 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 5.5 glucose, pH 7.3 with NaOH. On 
the day of the experiment, cell plates were washed 3-times with the assay buffer using the 
EMBLA instrument (Skatron) and 20 µL of buffer was left in each well. 20 µL of Fluo-4AM 
(Molecular Probes) buffer was added to each well to give a final concentration of 2 µM and 
cells were then incubated at room temperature for 60 min in the dark. After the loading 
incubation, cell plates were washed 3-times to remove unloaded Fluo-4 and 30 µL of buffer 
was left in each well. Then cell plates were placed into the Fluorescent Imaging Plated 
Reader (FLIPR) instrument with 1 W laser power, 10 % gain and 0.4 s exposure and a dual 
addition protocol of 10 min fluorescence measurement was used. Compounds were received 
in 384-well plates at a concentration of 10 mM. A serial dilution (1:3) was performed using a 
Beckman FX. A copy of the serial dilution plates was prepared and diluted with buffer 
immediately prior to the experiment. The first 10 µL addition into a well was from a buffer 
  
pre-diluted compound plate and it was followed by 10 minutes incubation. AMPA positive 
modulators did not give rise to detectable calcium increases when applied in the absence of 
glutamate. Then in the second 10 µL addition glutamate was applied to give a final 
concentration of 100 µM. Glutamate caused a dramatic increase in FLIPR counts when a 
positive modulator was pre-applied. Cyclothiazide (Sigma Aldrich) 150 µM, a known AMPA 
receptor positive modulator, was used as positive control. 
Intracellular calcium measurements through NMDA receptors were similar to that described 
for AMPA receptors except for the addition of 500 µM ketamine hydrochloride during 
labelling with FLUO-4. Calcium influx measurements through kainate receptors were also 
similar to that described for AMPA receptors except for the addition of concanavalin A 
(Sigma Aldrich) 0.125 mg/mL which reduced the level of receptor desensitisation. 
Assay quality was determined by calculating the Z’ value: high (150 µM cyclothiazide and 
100 µM glutamate) and low controls (only 100 µM glutamate) were always present within 
each 384 well plate. FLIPR kinetics data were transformed to a single end point using the 
peak high of the response. Values were then normalized as the specific percent increase from 
the 100 µM glutamate effect (0 %) to the maximal cyclothiazide positive modulator effect 
(150 µM) in the presence of the 100 µM glutamate stimulation (100 %). In general, data from 
plates were only accepted if Z’>0.3 and 2 out of three pharmacological standards had     
values that were within 3x Standard Deviation of historical values. pEC50 for UoS12258 was 
calculated using a non-linear, 4 parameter logistic curve-fitting program. 
2.3 Recombinant receptor electrophysiology  
AMPA receptors: HEK293-hGluA2i unedited RC17 cells were grown in a DMEM medium 
supplemented with 10% FBS, 2 mM glutamine, 10% non-essential amino acids, 1% 
penicillin/streptomycin and 500 µg/mL geneticin (G418) in a 5% CO2 humidified atmosphere 
at 37 °C. Cells were plated on glass treated with poly-D-lysine (BD BioCoat coverslips, BD 
Biosciences Cat.No. 354086) at a density of 50,000-75,000 cells/mL (2mL of cell suspension 
were applied to 35x10 mm Petri dish containing the glass coverslips), kept at 30°C and used, 
respectively, 1 and 2 days after plating. Experiments were carried out at room temperature.  
NMDA receptors: HEK293-MSRII cells (passages 19-23) were seeded onto 12 mm poly-D-
lysine coated coverslips (100,000 cells per 35 mm petri dish holding 3 coverslips) and the 
cells were transfected 24 h after seeding. The following DNAs: hNR1A (0.55 µg), hNR2B 
(2.8 µg) and pCMS-EGFP (0.8 µg) were added to the petri dish in the presence of optimem 1 
  
(0.25 mL; Invitrogen) and lipofectamine 2000 (9 µL) and incubated for 4 h at 37 °C in an 
atmosphere of 5% CO2. After rinsing off the transfection medium, the cells were maintained 
in culture medium containing 0.3 mM MgSO4 plus 200 µM D-2-amino-5-phosphonovaleric 
acid (D-AP5; NMDA receptor antagonist), at 30 °C in an atmosphere of 5% or 10% CO2 for 
24 h prior to commencing electrophysiological recordings. 
The external recording solution comprised (in mM), 140 NaCl, 2 KCl, 1 MgCl2, 2 CaCl2, 10 
glucose, and 12 HEPES, pH 7.35 (with NaOH). The intracellular solution comprised (in mM) 
150 CsCl, 10 EGTA, and 10 HEPES, pH 7.3 (with CsOH). For perforated patch-clamp 
recordings, intracellular solution containing 240 µg/mL amphotericin B was used to backfill 
the pipette while intracellular solution alone was used to fill the tip. Glutamate (Sigma 
Aldrich) was dissolved in H2O to generate a 1 M stock solution. Cyclothiazide (Sigma 
Aldrich) was dissolved in DMSO to generate a 100 mM stock solution. 
Whole-cell currents were recorded from cells using the perforated patch-clamp technique 
(Hamill et al., 1981; Sherman-Gold, 1993), using the EPC9 or EPC10 patch-clamp system 
and the Pulse program (HEKA). Patch pipettes were pulled from thin-wall borosilicate glass 
capillary (1.5 mm outer diameter) using a P-97 pipette puller (Sutter Instruments) and had 
resistances of 2-5 MΩ. Cells were discarded unless the seal formation permitted low 
resistance access within 10 min (series resistance ≤ 20 MΩ) due to the amphotericin B. 
Results were not used when the access resistance changed significantly during the 
experiment. Exchange of solution around the cell was achieved by holding the cell in front of 
one of 16-48 channels with a constant solution flow and quickly (10-50 ms) moving the chip 
to place an adjacent channel in front of the cell (Dynaflow). 
The cell was clamped at -60 mV. Automatic series resistance and capacity compensation 
were applied and checked regularly. The current induced by a 1 s application of the agonist 
was recorded. The agonist application was repeated every 60 s. Control currents elicited by a 
fixed concentration of agonist (3 mM, approximate EC50 ) were recorded during the 
experiment in order to monitor any variations in charge. For the concentration response 
curve, the area under the curve of the current for the first  500 ms (charge) was measured for 
the control application of glutamate alone and for glutamate in the presence of increasing 
concentrations of the positive modulator (5 different concentrations from 10 nM up to 100 
µM) in the same cell. Cyclothiazide (Sigma Aldrich) 30 µM, a known AMPA receptor 
positive modulator, was used as positive control. 
  
Concentration response curves for positive modulator were fitted to the equation of the form: 
Y=Top/ (1+10(Log EC50-X)*Hill Slope) 
Y is the response in % normalised to 30 µM cyclothiazide, Top is the extrapolated or 
asymptote maximal % of potentiation, X is the logarithm of concentration. Y starts at 0 and 
goes to the top with a sigmoid shape. Graphs were constructed by averaging the results from 
all experiments and fitting a single curve to the pooled data. 
2.4 Native receptor electrophysiology 
Neuronal cultures were prepared from embryonic rat brains harvested following sacrifice of 
the pregnant female by CO2 inhalation in accordance with GlaxoSmithKline animal welfare 
guidelines and the U.K. Animals (Scientific Procedures) Act 1986. The dissected hippocampi 
were placed into ice-cold Hank’s Balanced Salt Solution (HBSS) comprised of: pyruvate, 1 
mM; penicillin, 100 mg/mL; streptomycin, 100 mg/mL; HEPES, 10 mM; NaHCO3, 0.035%, 
Ca2+- and Mg2+-free.  The tissue was then trypsinised for 30 min at 37 °C in trypsin/EDTA 
diluted (final concentration 0.05%) in HBSS with sodium pyruvate (Ca2+- and Mg2+-free). 
Tissue pieces were physically dissociated and neurons were plated onto poly-D-lysine coated 
coverslips in plating medium comprised of: Neurobasal Medium + 1 mM sodium pyruvate; 
penicillin, 100 mg/mL; streptomycin, 100 mg/mL; B27 supplement 1x; L-glutamine, 1 mM. 
Half of the culture medium was replaced twice weekly and the cells were used for recordings 
after 5 to 13 days in culture. 
AMPA receptors: Extracellular solution comprised (in mM), NaCl 145, KCl 2.5, HEPES 10, 
glucose 10, CaCl2 1.5, MgCl2 1.2; pH 7.3 with NaOH. Intracellular solution comprised (in 
mM), CsF 80, CsCl 80, HEPES 10, MgATP 14, DiTRIS creatine phosphate 14, creatine 
phosphokinase 50 U/mL;  pH 7.3 CsOH. UoS12258 was dissolved in DMSO to generate a 
100 mM stock solution. Test solutions were diluted to concentrations between 10 nM and 100 
µM from this stock using extracellular solution (maximum final DMSO concentration 
≤0.1%). AMPA (Tocris-Cookson) was dissolved in  H2O to generate a 10 mM stock. All 
experiments were performed at 20-21 °C. Whole-cell voltage-clamp recordings from rat 
cultured hippocampal neurons were made using standard methods (Hamill et al 1981). 
Briefly, using an Axopatch 200B amplifier and pClamp 8.0 software (Axon Instruments) 
each cell was held at -70 mV throughout the recording and solution exchange was achieved 
using a fast-step 2 tube perfusion system (Biologic  RSC 160). Control AMPA receptor-
  
mediated currents were evoked by rapidly moving from normal extracellular solution to 
extracellular solution containing 30 µM AMPA, (previously determined approximate EC50) 
for 2 s then returning to normal extracellular solution for 30 s. This cycle of solution changes 
was repeated continuously throughout the baseline recording period. The lowest test 
concentration of UoS12258 was added to both perfusion tubes and the solution change cycle 
repeated until a stable current was measured. Test concentrations were increased sequentially. 
Inward currents induced by AMPA application were complex in that their magnitude and 
duration depended on three different mechanisms: (1) opening of the AMPA receptor channel 
measured in terms of peak amplitude, (2) desensitization of AMPA receptors measured as the 
degree of relaxation of the inward current from its initial peak amplitude to a reduced steady 
state plateau level in the continued presence of AMPA and (3) deactivation of AMPA 
receptors measured as the rate at which the inward current decayed back to baseline 
following termination of the AMPA application. 
Peak current amplitude was measured as the difference between baseline current and the 
maximum inward current detected following fast perfusion application of either AMPA alone 
or AMPA + UoS12258. Peak current amplitude, measured at each concentration of 
UoS12258 in the presence of 30 µM AMPA, was normalised to the peak current amplitude 
after application of AMPA alone. Desensitisation of AMPA receptors is a measure of the 
reduction from peak inward current amplitude to a steady-state current influx in the continued 
presence of AMPA. AMPA receptor deactivation is the rate at which the inward current 
returns to baseline after agonist removal and is represented by the decay constant, tau, of a 
mono-exponential curve fitted to the relaxing inward current after AMPA application has 
stopped. The tau value, measured after each concentration of UoS12258 in the presence of 30 
µM AMPA, was normalised to the value of tau after application of AMPA alone. Each of 
these parameters was measured and analysed using Clampfit 8.0 (Axon Instruments), Excel 
(Microsoft) and Origin (Microcal). The statistical significance of differences in each of the 
measured parameters described above was assessed using a Student’s paired t-test (Excel). 
 
NMDA receptors: Extracellular solution comprised (in mM): NaCl 145, KCl 2.5, HEPES 10, 
Glucose 10, CaCl2 1.5, Glycine (30 µM) – (Mg2+ Free to prevent NMDA receptor block). 
Intracellular solution comprised (in mM): K Gluconate 140, HEPES 10, NaCl 17, MgATP 4, 
NaGTP 0.3; pH 7.3 KOH 
  
Baseline whole cell currents were evoked by rapidly exchanging the perfusing medium from 
extracellular solution to extracellular solution containing 100 µM NMDA for a period of 2 s. 
In contrast, test currents were evoked by rapidly exchanging the perfusing medium from 
extracellular solution containing 100 µM UoS12258 to extracellular solution containing 100 
µM UoS12258 plus 100 µM NMDA for a period of 2 s. As with baseline currents each test 
pulse was separated from the next by a 30 s interval. 
Kainate receptors: Extracellular solution comprised (in mM): NaCl 145, KCl 2.5, HEPES 10, 
glucose 10, CaCl2 1.5, MgCl2 1.2; pH 7.3 with NaOH. Intracellular solution comprised (in 
mM): CsF 80, CsCl 80, HEPES 10, MgATP 14, DiTRIS Creatine Phosphate 14, Creatine 
Phosphokinase 50 U/mL; pH 7.3 CsOH. Baseline whole cell currents were evoked by rapidly 
exchanging the perfusing medium from extracellular solution containing 100 µM SYM2206 
(a selective non-competitive AMPA receptor antagonist) to extracellular solution containing 
100 µM SYM2206 plus 100 µM kainate for a period of 2 s. In contrast, test currents were 
evoked by rapidly exchanging the perfusing medium from extracellular solution containing 
100 µM SYM2206 plus 100 µM UoS12258 to extracellular solution containing 100 µM 
SYM2206 plus 100 µM UoS12258 plus 100 µM kainate for a period of 2 s. As with baseline 
currents each test pulse was separated from the next by a 30 s interval. 
2.5 In vivo electrophysiology 
All animal studies were ethically reviewed and carried out in accordance with Animals 
(Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of 
Animals. GlaxoSmithKline safety regulations were adhered to at all times. 
Adult male Lister Hooded rats (Charles River) weighing 243-340 g were housed under a 12 h 
light/dark cycle with food (Harlan Maintenance Diet) and water available ad libitum. 
For electrophysiological recordings rats were prepared individually. Specifically, once 
removed from their home cage they were placed in an induction chamber and anaesthetised 
with 5% isoflurane in a 1:1 mix of oxygen and nitrous oxide which was adjusted to 2.5% 
isoflurane to maintain anaesthesia throughout the surgical procedure. Surgery involved 
cannulating the jugular and femoral veins using Portex tubing such that the cannula projected 
externally from the animal. Each rat was then placed in a stereotaxic frame and secured with 
atraumatic ear bars. Body temperature was monitored and maintained at appropriate levels by 
means of a thermostatically-controlled heated blanket and rectal probe. A midline incision 
  
was made to expose the dorsal aspect of the skull and a burr hole made to allow implantation 
of a multi-barrelled electrode (Kation Scienitific, Hungary) into the CA1 region of the 
hippocampus (from Bregma: AP -4.2 mm, ML 2.4 mm, depth 1.8-2.2 mm). The multi-
barrelled electrode consisted of a carbon fibre recording electrode and 3 glass barrels two of 
which were filled with the following solutions: one barrel contained 2 % w/v methylene blue 
dissolved in 0.5 M sodium acetate which acted as the balance for the current ejection and the 
second barrel contained 5 mM AMPA. A silver ground electrode was also positioned under 
the skin margin. Isoflurane levels were lowered to 1.75% prior to commencing recordings. 
Neuronal activity was recorded using a Neurolog NL100 AK head stage connected to a 
NL104A AC preamplifier. The signal was filtered (0.5 - 5 kHz), passed through a Humbug 
Noise eliminator and fed into an audio amplifier and a CED 1401 digital analogue interface. 
Spike 2 software (CED) was used to record neuronal activity. AMPA was ejected via 
iontophoresis (currents of 4-40 nA for periods of 40 s, repeated at intervals of 40-60 s.  
UoS12258 was prepared as a nano-milled formulation in 1 % w/v HPMC (Pharmacoat 603) / 
0.1 % sodium lauryl sulphate (Sigma-Aldrich) in purified water.  The diluent and vehicle 
was1 % w/v HPMC / 0.1 % sodium lauryl sulphate and all i.v. doses of UoS12258 were 
administered as 0.05 mL per 100 g. For oral dosing the same batch of UoS12258 that was 
used for i.v. dosing was administered (Batch number: VNAA\6768\149\4), vehicle was 1% 
methylcellulose and dose volume was 2 mL/kg in all cases.  AMPA (Sigma-Aldrich) was 
prepared as 5 mM stock solution in 0.9% saline (pH8). 
For acute administration animals were divided into two groups, UoS12258 (n=4) and saline 
(n=3). Once a minimum of 5 consistent and consecutive responses to AMPA application had 
been achieved either UoS12258 or saline were dosed. In this respect, rats in group one were 
intravenously dosed with UoS12258 in a cumulative dosing paradigm consisting of 0.5, 1.0, 
and 1.5 mg/kg doses delivered at 20 minute intervals. A similar procedure was used for the 
second group of rats except that 3 doses of saline were administered intravenously at 
20 minute intervals. For sub-chronic administration of UoS12258 animals were divided into 
four groups: vehicle-vehicle (n=5); vehicle-UoS12258 (n=5); UoS12258-UoS12258 (n=5) 
and UoS12258-vehicle (n=5) where the first treatment term indicates how the animals were 
dosed for the seven day period leading up to the test treatment on day 8; this latter treatment 
being indicated by the second treatment term. The dose of UoS12258 used for sub-chronic 
dosing was 0.03 mg/kg (p.o.) in a dose volume of 2 mL/kg and the vehicle was 1 % 
methylcellulose (p.o.).  All animals were dosed at approximately 9 am every day for 7 days. 
  
Animals receiving UoS12258 on the test day were dosed intravenously using a cumulative 
dosing paradigm comprising of 0.1, 0.5 and 1.0 mg/kg at 20 minute intervals whereas animals 
receiving vehicle on the test day received 3 doses of saline at 20 minute intervals. 
Brains and blood samples (50 µL) were collected at the end of each experiment and frozen at 
-80 °C in brain and EDTA tubes, respectively, until analyzed. UoS12258 content was 
determined by liquid chromatography/tandem mass spectrometry (LC-MS/MS) using a 
Quattro Premier (Micromass) mass spectrometer with positive-ion electrospray ionisation. 
2.6 Novel object recognition 
Adult male Lister Hooded rats (Charles River) weighing 250-320 g on the day of testing were 
housed in groups of 4 in the absence of environmental enrichment (sawdust and bedding 
only) and maintained on a 12 h light/dark cycle with lights on at 06:00 GMT.  Food (Harlan 
Maintenance Diet) and water were available ad libitum. For all experiments rats were 
habituated to Perspex test arenas (42 l x 21 w x 20 h cm) for 60 min (am) and 3 min (pm) on 
the day prior to testing. For experiments 1 and 2 rats were sham dosed with vehicle on four 
occasions prior to testing. On the first test day, rats were placed in a test arena for a 3 min 
habituation period and then presented with 2 identical objects (T1, 3 min). 24 h later rats were 
placed back in the test arena and presented one of the previous (familiar) objects and a novel 
object (T2, 3 min). Objects used were similar sized black plastic ‘kong’ and cylinder shapes 
(approximately 6.5 h x 6 w cm). Objects were cleaned with 70% ethanol between animals to 
remove any odour trace. The novel object and novel object side (left or right) was randomised 
equally across all treatment groups. The time spent exploring the objects during T1 and T2 
was recorded by an observer blind to the novel object. Rats received UoS12258 or vehicle by 
oral gavage (p.o.). Treatment group sizes were n = 12 unless stated otherwise. For acute 
studies rats were dosed 4 h prior to both T1 and T2 at 0.1, 0.3 and 1 mg/kg p.o. For sub-
chronic studies rats were dosed once daily (8-10 am) for 7-days followed by a single dose 4 h 
prior to T1 (day 8) and T2 (day 9) at 0.003, 0.01 and 0.03 mg/kg p.o. 
In a separate study  male Lister Hooded rats were administered with two doses, 24 h apart, of 
UoS12258 (0.1, 0.3 and 1 mg/kg p.o.) separated by 24 h to simulate the dosing conditions 
used in acute behavioural studies. Animals were culled 4 h after the final dose following 
schedule 1 procedures, blood and brain samples were taken for analysis. For sub-chronic 
experiments animals were culled immediately following testing in T2 (n = 3) and blood and 
brains removed for analysis (as detailed for in vivo electrophysiology). 
  
2.7 Water maze 
This paradigm is used to investigate spatial learning and memory where learning and 
subsequent retention of the location of a hidden platform are measured. Aged rats show an 
inherent deficit in this paradigm such that they do not show an improvement in acquisition of 
the platform position over the course of training and therefore fail to learn where the platform 
is located as assessed during the probe tasks performed at the end of training. The effects of 
sub-chronic administration of UoS12258 (0.3, 1, 3, 10 mg/kg p.o.) upon age-induced 
cognitive deficits were determined in aged (22 month old) male Wistar rats. UoS12258 was 
administered once daily in 1% methylcellulose for 8 days prior to training and then on each 
training day (3 h prior to session) and also during the recall period, consistent with previous 
dosing protocols. Plasma samples were not taken from this study. During each trial, the 
latency to find the hidden platform (to a maximum of 90 s) was recorded. Animals received 5 
trials per day (inter-trial interval of 300 s) for 4 days. Recall of platform position was 
assessed by a probe test at 1, 3 and 7 days following the final training session, in which the 
platform was removed and animals were allowed to explore the maze for 30 s. The time spent 
in each quadrant was recorded.  
2.8 Passive avoidance 
The passive avoidance (PA) procedure is based on the ability of rats to associate a specific 
context (dark chamber) with an aversive conditioned stimulus (0.75 mA, 0.5 s scrambled foot 
shock). This experiment investigated the effects of acute UoS12258 on a scopolamine (0.08 
mg/kg i.p.)-induced deficit in PA in male Wistar rats. UoS12258 (0.1, 1, 3, 10 mg/kg p.o.) 
with the 5-HT6 receptor antagonist, SB-399885T (10 mg/kg p.o.) used as a positive control. 
Test drugs were administered in 1% methylcellulose 3 h prior to the onset of training. 
Scopolamine hydrobromide (0.8 mg/kg i.p.) was dissolved in saline and administered 6 h post 
training. Plasma samples were not taken from this study. On the training day rats were treated 
with vehicle or UoS12258 3 hours prior to assessment of spontaneous activity in the open 
field apparatus. Immediately afterwards the rats were placed in the light compartment and the 
latency to enter the dark chamber was recorded. Upon entering the dark compartment, rats 
received a foot shock (0.75 mA, 0.5 s) and returned to the light chamber whereupon they 
were returned to their home cage. Recall of this inhibitory stimulus was evaluated 24 h post-
training by returning the animal into the light chamber and recording the latency to enter the 
  
dark chamber up to a maximum of 600 s. At no point during the test period was foot shock 
given.  
2.9 Microdialysis.  
Male Lister Hooded rats (250-275 g) were housed in groups of four, kept under a 12h 
light/dark schedule, lights on at 07:00 with food and water available ad libitum. 
General anaesthesia was induced using isoflurane. Once deep anaesthesia had been obtained 
rats were administered synulox (antibiotic; s.c.) and rimadyl (analgesic; s.c.), and the rat 
transferred to a stereotaxic frame.  The skull was exposed and holes drilled relative to the 
Bregma, four anchor screws (1.6x3 mm stainless steel cheese head screws, Wood and 
Hughs), and additional holes drilled at 12 degrees to the dura surface for placement of 
microdialysis guide cannula (CMA 11, CMA, UK) into the dorsal hippocampus (AP: + 3.5 
mm, ML -2.0 mm, and DV – 2.0) and anterior cingulate cortex (AP: + 2.7 mm, ML -1.6mm, 
and DV – 2.0 mm) according to Paxinos and Watson (1986). Probe and anchor screws are 
secured in place with dental cement (Poly-F-plus, zinc polycarboz cement, Cladius Ashe) and 
the wound sealed. Postoperative fluids (5 mL saline, 2.5mL per side; s.c.) and analgesic 
(Nubain 0.4 mL/100 g; s.c.) were administered to aid recovery.  The rats were monitored 
until they regain their righting reflex and received at least 5 days post-operative care.  
18 h prior to the start of the dialysis experiment rats were moved into microdialysis cages 
(285 mm diameter, 355 mm high; manufactured in-house) to allow for overnight 
acclimatisation to the dialysis procedure room. On the morning of each experiment, 
microdialysis probes (CMA 11, 14/02, Linton Instruments; 2 mm active membrane) were 
perfused with a buffered artificial cerebral spinal fluid (aCSF) solution (comprising in mM: 
145 NaCl, 2.7 KCl, 1 MgCl2, 1.2 CaCl2 and 2 Na2HPO4) at 1μL / minute via a dual-channel 
liquid swivel (Instech 375/D/22QE microdialysis swivel, BAS). Microdialysis probes were 
inserted into the implanted guide cannulae and perfused with aCSF for 2 h before sampling 
began to allow for equilibration of neurotransmitter levels, following which samples were 
collected every 30 min. 4 dialysate samples were collected to generate baseline readings 
before administration of either test compound UoS12258 was dissolved in 1% 
methylcellulose and sonicated prior to administration.  Doses of UoS12258, 0.1, 0.3, and 1 
mg/kg or vehicle (1% methylcellulose) were administered in a volume of 2ml/kg; p.o. 
Following administration of compound, a further 10 dialysate samples were collected until 
the end of sampling. Dialysate samples were analysed for 5-HT, DA and NA using high 
  
performance liquid chromatography (HPLC) with electrochemical detection (ECD) and ACh 
using mass spectrometry. At the end of each experimental day, animals were returned to their 
home cage and re-used in a randomised cross-over design, allowing at least 7 days drug 
washout before subsequent uses. After the final experiment brains were removed and stored 
in formalin solution for probe placement verification.  
All dialysate samples were calculated as a subsequent percentage of the average absolute 
levels of neurotransmitters from the four baseline samples prior to administration of 
compound.  Significant differences between groups of the same compound were calculated 
by repeated measures analysis of variance (ANOVA) followed by Fischer’s least significance 
difference (LSD) post-hoc test where appropriate  with significance set at P < 0.05 (Statistica 
v6.0). 
 
2.10 Maximal electroshock threshold (MEST) test 
Adult male Sprague Dawley  or Lister Hooded rats (Charles River) weighing  95 to 160 g on 
the day of testing  were housed in groups of 6 or less and maintained on a 12 h light/dark 
cycle with lights on at 06:00 GMT.  Food (Harlan Maintenance Diet) and water were 
available ad libitum. Treatment groups of 12 animals were administered UoS12258 at 10, 30 
or 100 mg/kg by oral gavage (p.o.) two hours before testing (expt 1) or 30 mg/kg p.o. two, 
five or seven hours before testing in Sprague Dawley rats (expt 2) or 1.0, 3.0, 10 mg/kg four 
hours before testing in Lister Hooded rats (expt 3).  In all experiments the known pro-
convulsant, picrotoxin (2.0 mg/kg as a positive control) was administered i.p. 30 min before 
testing.  After dosing the animals were returned to their home cages.  Testing occurred in a 
separate room and consisted of assessing the induction of a tonic hind limb extensor seizure 
following a 0.1 s shock administered via corneal electrodes according to the 'up and down' 
method (Kimball et al.,1957).  In all experiments a separate group of animals (n=3 per dose) 
were dosed and blood and brain samples taken at the appropriate pre-treatment time for 
analysis of compound levels. The threshold for tonic hind limb extensor seizures was 
determined using a Hugo Sachs Elektronic stimulator which delivered a constant current of 
0.1 second duration, 50 Hz, sine wave form, fully adjustable between 1 to 300 mA, via 
corneal electrodes.  The electrodes were briefly immersed in saline before application of the 
electroshock in order to achieve good electrical contact. 
  
3. Results  
3.1 Functional activity at recombinant human GluA2i homomeric AMPARs. 
The functional activity of UoS12258 at the hGluA2i homomeric AMPAR stably expressed in 
HEK293 cells was assessed using FLIPR/Ca2+ influx methodology. Application of glutamate 
(100 µM) alone did not elicit a signal due to rapid AMPAR desensitisation. However, in the 
presence of UoS12258, application of glutamate consistently increased intracellular Ca2+ 
levels such that an increase in the concentration of UoS12258 produced a progressive 
potentiation of glutamate-induced responses. A non-linear, 4-parameter logistic curve-fit of 
the data generated pEC50 and maximum potentiation values (relative to the established 
AMPAR positive modulator cyclothiazide (150 µM)) of 5.57 ± 0.07 and 100.7 ± 3.9 % (mean 
± sem), respectively (n = 6; Figure 1). When applied alone, in the absence of glutamate, 
UoS12258 did not affect intracellular Ca2+ levels indicating that it possessed no intrinsic 
agonist activity. 
Figure 1 
3.2 Electrophysiological Activity at human recombinant GluA2i homomeric AMPARs. 
Using this approach, UoS12258 potentiated glutamate-induced whole-cell, AMPAR–
mediated currents producing a maximal response that amounted to 112 ± 32% of the maximal 
response induced by the reference AMPAR positive modulator cyclothiazide (30 µM). The 
pEC50 value (5.19 ± 0.02 (mean ± sem; n = 4) Figure 2) for this positive modulatory effect of 
UoS12258 was in close agreement to that generated using the FLIPR/Ca2+ influx assay 
described above. 
Figure 2 
3.3 Functional activity at recombinant human GluA1i, GluA3i, GluA4i and rat GluA2i 
homomeric AMPARs 
To demonstrate (a) the broad spectrum positive modulatory activity of UoS12258 across 
AMPARs formed from different GluA subunits, and (b) lack of species dependent 
pharmacology, FLIPR-based assays were used to assess its activity at human AMPARs 
formed by homomeric assembly of GluA1i, 3i or 4i subunits as well as homomeric assembly 
of rat GluA2i subunits transiently transfected into HEK293 cells (Table 1). There was less 
than a 10 fold difference between pEC50 values for all hGluAi homomeric AMPARs and 
  
between rat and human GluA2i indicating that UoS12258 possesses little specificity for 
individual GluA subunits or across species. (Supplementary Table 1). 
3.4 Potentiation of rat native AMPA receptor-mediated responses. 
Repeated (2 s duration, every 30 s) applications of 30 µM AMPA in rat cultured hippocampal 
neurons produced inward currents, the peak amplitude and waveform of which were 
consistent in magnitude between successive applications. Measurements taken reflected the 
three different mechanisms which occurred during this period: (1) opening of the AMPAR 
channel measured in terms of peak amplitude, (2) desensitization of AMPARs measured as 
the degree of relaxation of the inward current from its initial peak amplitude to a reduced 
steady state plateau level in the continued presence of AMPA and (3) deactivation of 
AMPARs measured as the rate at which the inward current decayed back to baseline 
following termination of the AMPA application. 
Whilst UoS12258 alone did not evoke a whole-cell inward current at any concentration tested 
(10 nM - 100 µM), application of 30 µM AMPA in the presence of UoS12258 produced 
inward currents that exhibited larger peak amplitudes, reduced desensitization and slowed 
deactivation which all contributed to an increase in charge transfer (area under the inward 
current), relative to control responses in the absence of UoS12258. The effect of UoS12258 
on each of these electrophysiological parameters was clearly concentration-dependent and 
was first evident in the nM concentration range. 
Thus, although the pEC50 and maximal potentiation of charge transfer induced by UoS12258 
were 5.1 and a 4.1 ± 0.97 fold increase, respectively, 10 nM UoS12258 produced a 
statistically significant 1.4-fold increase in charge transfer when compared to AMPA alone (* 
n = 8; P<0.01, paired t-test, Figure 3A). 
UoS12258 produced a concentration-dependent increase in the rate constant of AMPAR 
deactivation (pEC50 5.3) such that at 100 µM the rate of deactivation was 5.9 ± 1.5-fold 
greater than that produced by AMPA application alone. As with charge transfer UoS12258 
also potentiated this component of the AMPAR-mediated response at nM concentrations such 
that at 10 nM it produced a 44 ± 6% decrease in the rate of deactivation (* P<0.05, paired t-
test n = 7; Figure 3B).  
In contrast to the significant increases in both charge transfer and rate of deactivation, 
inhibition of AMPAR desensitisation by UoS12258 was more variable and only statistically 
  
significant at concentrations of 10 µM and above where a greater than 52 ± 17% reduction in 
AMPA receptor desensitisation was observed (n = 7, * P<0.05, paired t-test, Figure 3C).  
Notably, since the minimum effective concentration of UoS12258 on desensitization was 10 
µM the previously described potentiation of charge transfer at 10 nM reflects UoS12258-
mediated potentiation due to changes in peak amplitude and deactivation (Supplementary 
Table 2). 
Figure 3 
3.5 Selectivity versus recombinant NMDA and kainate receptors. 
In the NMDA receptor FLIPR assay UoS12258 (tested up to 50 µM, n=4) did not show any 
activity both as opener and blocker at human GluN1/2B receptors. Similarly, in 
electrophysiology experiments UoS12258 did not potentiate GluN1/2B receptor mediated 
activity at either 10 nM, the minimum concentration (P=0.87, paired t-test, n=5) or 1 µM, 
100 times the minimum concentration (P=0.18, paired t-test, n=5) shown to potentiate 
AMPA-mediated currents; although there was a partial inhibition (18 ± 1% at 100 µM, P = 
0.049, paired t-test, n=5) when tested at 100 µM.  
In FLIPR experiments on transiently expressed GluK1 (Q-edited) homomeric kainate 
receptors UoS12258 (up to 50 µM, n=3) did not show any activity either as an agonist, 
antagonist or positive modulator. Identical results were obtained using electrophysiological 
analysis.  
3.6 Functional selectivity versus rat native NMDA and Kainate receptors. 
In separate neurons, repeated applications of either NMDA, in the presence of NMDA 
receptor co-agonist glycine, or kainate, in the presence of the selective AMPA receptor 
antagonist SYM2206, generated reproducible inward currents that were mediated by 
activation of NMDA receptors and kainate receptors, respectively and that were not 
significantly affected by UoS12258 (100 µM) (n = 4 for both; P = 0.06 for NMDAR-
mediated responses and P = 0.89 for kainate receptor-mediated responses, paired t-test). 
There were also no significant changes in NMDA receptor-mediated charge transfer with 
UoS12258 at either 10 nM, the minimum concentration (P=0.16, paired t-test, n=4) or 1 µM, 
100 times the concentration (P=0.69, paired t-test, n=4) shown to potentiate AMPA-mediated 
currents. 
  
3.7 Potentiation of AMPA receptor-mediated synaptic responses in vivo. 
The effect of UoS12258 was evaluated in vivo in an electrophysiological model where 
synaptic connectivity is intact, specifically the potentiation of electrically evoked AMPAR-
mediated synaptic potentials recorded from the dentate gyrus of the anaesthetised rat. 
Electrical stimulation of the medial perforant pathway evoked a population spike recorded in 
the hippocampal dentate gyrus granule cell layer. UoS12258 (0.1 mg/kg i.v.) significantly 
increased population spike amplitude by 18 ± 3 % compared to vehicle (Figure 4, P<0.05, 
n=4 ANCOVA, univariate test of significance. Analysis of brain samples taken immediately 
after the experiment generated a mean UoS12258 concentration of 198 ± 40 ng/g). Brain 
tissue binding for UoS12258 was measured as 97.4 % resulting in an estimated mean 
unbound concentration of 5.1 ng/g, which equates to an approximate free concentration of 15 
nM, which is in close agreement with the MEC (10 nM) for UoS12258 induced potentiation 
of AMPAR-mediated charge transfer and deactivation in rat hippocampal neurons. 
Figure 4 
3.8 Novel Object Recognition (NOR Test). 
The NOR test is a two-trial recognition memory test of the ability of rats to discriminate 
between novel and familiar objects. NOR can be impaired by inserting a time delay (24 h) 
between presentations of the objects.  
Data are expressed both as total time spent exploring the novel and familiar objects in T2 and 
as the d2 index (proportion of time exploring the novel object in T2). In the first study acute 
UoS12258 (0.1, 1, 10 mg/kg) produced a bell-shaped dose response curve (i.e. improvement 
in object recognition at 1 mg/kg with a loss of effect at 10 mg/kg). At the higher dose 1 rat 
out of 12 had a seizure and was excluded from the test. Based on an efficacious dose of 1 
mg/kg, a follow up experiment, was conducted to assess a lower dose range (i.e. 0.1-1 mg/kg 
p.o.). Following acute administration, UoS12258 significantly increased novel object 
exploration compared to vehicle treated rats at 0.3 mg/kg (P<0.05) and 1 mg/kg (P<0.01, 
Figure 5A) and the d2 index (P<0.01, Figure 5A). In a separate study, mean blood and brain 
levels of UoS12258 were determined in rats dosed under identical conditions (n = 3) and are 
shown in Supplementary Table 3. 
Following 7-days sub-chronic dosing plus treatment 4 h prior to T1 and T2, UoS12258 
significantly increased novel object exploration compared to vehicle treated rats at 0.03 
mg/kg (P<0.05, Figure 5B). The d2 index was significantly increased at both 0.01 and 0.03 
  
mg/kg (P<0.01, Figure 5B). The sub-chronic MED was determined as 0.03 mg/kg based on 
significant changes in both measures. Mean blood and brain levels of UoS12258 in rats 
sampled immediately after testing are presented in Supplementary Table 4 (n = 3). A 
previous sub-chronic NOR study with UoS12258 (0.03, 0.1, 0.3 mg/kg) also exhibited a bell 
shaped dose-response curve with efficacy at 0.03 and 0.1 mg/kg and no effect at 0.3 mg/kg. 
Thus, two studies confirm that sub-chronic dosing of UoS12258 results in increased potency 
to facilitate novel object recognition learning, in accordance with data reported in the 
literature for compounds of this class. 
Figure 5 
3.9 Passive Avoidance.  
Neither UoS12258 nor SB-399885T (5-HT6 receptor antagonist) had any effect on 
spontaneous open field activity (data not shown), suggesting a lack of confounding motor 
effects. Scopolamine impaired passive avoidance (P<0.0001, Figure 6). UoS12258 (10 
mg/kg) did not impair performance when given alone, and prevented the scopolamine-
induced impairment in a dose-dependent manner (P<0.0001), with significant effects 
observed at 3 and 10 mg/kg (P<0.05). The positive control SB-399885T also prevented the 
scopolamine-induced memory deficit (P=0.0003).  
Figure 6 
3.10 Morris Water Maze in Aged Rats. 
UoS12258 significantly reduced escape latencies following 3 and 10 mg/kg (Figure 7; 
F[1,180]=14.1 and 5.9, P=0.0002 and 0.0156 for 3 and 10 mg/kg, respectively, vs. vehicle-
treated controls). 
UoS12258 significantly reduced swim angle, the angle between start position and the position 
of the hidden platform in the water maze, over the 4 training sessions (F[1,36] = 19.7 and 5.1; 
P<0.0001 and P = 0.03 for 3 and 10 mg/kg, respectively, vs. vehicle-treated), suggesting an 
improved search strategy (data not shown). UoS12258 had variable effects upon swim speed, 
i.e. no consistent increase in swim speed at doses shown to be efficacious at improving 
acquisition, which therefore does not explain the reduced latency to find the hidden platform. 
Figure 7 
  
Recall of the hidden platform position was assessed by probe trials carried out 1, 3 and 7 days 
following the final training session. UoS12258 (3 mg/kg) improved recall of the task in all 3 
probe trials (Figure 7, P<0.05, Mann-Whitney U-test). UoS12258 (10 mg/kg) significantly 
improved recall in the 1 day post-training probe trial only. 
Figure 8 
3.11 Microdialysis 
UoS12258 significantly (F3,23=5.94, P<0.01) increased extracellular levels of acetyl choline 
(ACh) in both the anterior cingulate cortex at all 3 doses (0.1 mg/kg, P<0.001, 0.3 mg/kg, 
p<0.05 and 1.0 mg/kg, P<0.01) and a significant (F3,22=5.076, P<0.001) increase in the dorsal 
hippocampus again at all 3 doses (0.1 mg/kg, P<0.05, 0.3 mg/kg, P<0.001 and 1.0 mg/kg, 
P<0.005, Figure 9).  
Figure 9 
UoS12258 also induced a significant (F3,24=4.47, P<0.05) increase in extracellular dopamine 
levels at both 0.3 mg/kg (P<0.05) and 1 mg/kg (P<0.01) (Figure 9). There was no significant 
effect of AMPA positive modulation on extracellular levels of 5-HT or noradrenaline (NA) in 
any of the brain structures studied.    
 
3.12 Side effect profiling using maximal electroshock seizure threshold (MEST) test. 
In order to assess the potency of UoS12258 to potentiate induced seizure activity, rats were 
pre-treated with the compound prior to induction of seizure. Corneal application of electrical 
current (CC50 approx. 60-70 mA, 0.1 ms duration) in the rat induces tonic and full tonic-
clonic seizures. In separate experiments UoS12258 was administered 10, 30, 100 mg/kg, p.o., 
2 h ptt; 30 mg/kg, p.o., 2, 5, 7 h ptt to Sprague Dawley (SD) rats; 1.0, 3.0 10 mg/kg, p.o., 4 h 
ptt to Lister Hooded (LH) rats before testing for pro-convulsant activity. Lister Hooded rats 
were chosen to provide a comparison with the NOR potency data.  
In SD rats, UoS12258, significantly decreased seizure threshold at 30 and 100 mg/kg by -
41% (3390 ng/g in brain) and -58% (4961 ng/g in brain), respectively 2 h post dose (Table 1). 
A subsequent DMPK study showed that concentration was equivalent at 2 h and 5 h. 
Therefore, in a repeat study, UoS12258 (30 mg/kg p.o.) was tested 2, 5 and 7 h post dose. 
Seizure threshold compared to vehicle (5 h ptt) was reduced at all time points by -54%, -43% 
and -57% (2, 5 and 7 h ptt respectively). At 2 h 1/13 animals and at 7 h 1/15 animals showed 
  
spontaneous convulsions and were culled just before testing. In LH rats (same strain as NOR 
studies), UoS12258 significantly reduced seizure threshold by -38% at 10 mg/kg 
(Supplementary Table 5). Both rat strains show similar brain exposure (2446 ng/g in LH vs. 
2283 ng/g SD at 10 mg/kg, respectively). 
Table 1 
  
  
4. Discussion 
In this article we present data from experiments that describe the pharmacological properties 
of UoS12258, a novel and selective AMPAR positive modulator.  Although, as stated earlier, 
many molecules have been investigated pre-clinically and several progressed into clinical 
trials, there is limited full disclosure of the enabling pre-clinical data sets – particularly 
regarding behavioural and tolerability data.  To address this situation, we disclose the full 
data set generated for this molecule which has progressed into clinical evaluation, including 
details of the differences observed in behavioural studies between acute and repeat dosing 
and also the clear side effects seen at elevated concentrations.  In addition to the studies 
reported below, a wider investigation was conducted of UoS12258 in additional behavioural 
pharmacology models, for which the data were either inconclusive: reversal of ketamine or 
amphetamine-induced hyperactivity in rat and reversal of quinelorane (D2/3 receptor 
agonist)-induced hypoactivity in rat, or only effective at high doses: mouse forced swim test 
(10 mg/kg po administered 240 min prior to test gave efficacy of imipramine dosed ip 30 min 
prior to test).  Full data for these studies are not included in this manuscript. 
4.1 Characterisation using recombinant systems 
We investigated the effect of UoS12258 on intracellular Ca2+ influx using FLIPR based 
assays and the results suggest that UoS12258 shows no clear subunit specificity and should 
act equipotently at heteromeric AMPARs with different subunit compositions, which exist in 
native tissues. Also, given that pEC50 values for UoS12258 were similar at rat and human 
there appears to be little evidence of species selectivity. Using the same recombinant system, 
HEK293-hGluA2i stable cell line with whole-cell voltage clamp electrophysiology the pEC50 
for UoS12258 was again similar to the FLIPR values with this AMPAR subunit.  
4.2 Characterisation using native systems 
Although rates of receptor activation and deactivation are comparable across all homomeric 
AMPARs and are therefore independent of AMPAR GluA subunit complement, 
desensitisation kinetics differ depending upon AMPAR subunit stoichiometry (see 
Schlesinger et al, 2005). As whole cell currents in neurons sample activation of a 
heterogeneous population of AMPARs that will differ from neuron to neuron it is likely that 
the observed variation in desensitization is due to the heterogeneity of the AMPAR 
populations assessed. Activation (charge transfer) and deactivation of AMPA receptors are 
  
measures that define the onset and offset of glutamatergic activity and are therefore directly 
relevant to the propagation of synaptic transmission and synaptic plasticity. Receptor 
desensitisation, during which the receptor becomes inactive in the continued presence of the 
ligand, has been more closely associated with excessive or pathological glutamatergic 
activity. In native hippocampal neurons using whole-cell voltage clamp electrophysiology it 
was possible to measure AMPA receptor-mediated charge transfer and deactivation which 
were potentiated significantly by concentrations of UoS12258 as low as 10 nM. It is 
interesting however, that the pEC50 of UoS12258 on charge transfer, desensitisation and 
deactivation of AMPA-mediated currents in native neurons are all in the same range as the 
pEC50 values in recombinant systems. There are clearly many physiological differences 
between recombinant and native systems for example increased levels of phosphorylation, the 
presence of transmembrane AMPA regulatory proteins (TARPs) or increased AMPAR 
expression at the cell membrane, which could explain the observed low concentration-
mediated AMPAR potentiation by UoS12258 in the native system. Perhaps more 
interestingly this concentration is comparable to the concentrations measured in the brain 
immediately after in vivo electrophysiological studies, in which UoS12258 increased AMPA 
receptor-mediated synaptic activity. Together these data mutually support the observation 
that, at equivalent concentrations, UoS12258 evoked significant potentiation of AMPAR-
mediated neuronal activity both in vitro and in vivo. 
Selectivity of UoS12258 for AMPA subtype glutamate receptors could however be a 
desirable property since activation and/or potentiation of other ionotropic glutamate receptor 
subtypes (i.e. NMDA and kainate) could cause excessive glutamate channel opening, 
increasing Ca2+ influx and leading to excitotoxic damage. To establish its selectivity for the 
AMPAR the functional activity (agonism, antagonism and positive modulation) of UoS12258 
was assessed at the human NMDAR1/2B heteromeric NMDA receptor and the human 
GRIK1 (Q) homomeric kainate receptor using both FLIPR/Ca2+ influx and 
electrophysiological methodologies.  
UoS12258 did not potentiate NMDAR1/2B receptor mediated activity at any concentration 
tested whether tested by Ca2+ influx or whole-cell patch clamp. Similarly, in FLIPR 
experiments on transiently expressed kainate UoS12258 did not show any activity either as 
an agonist, antagonist or positive modulator. Identical results were obtained using 
electrophysiological analysis. UoS12258 also produced no significant potentiation in activity 
  
at rat NMDA or kainate receptors suggesting that this compound exhibits selectivity for 
AMPA compared to other glutamate receptor subtypes. 
4.3 Cognition 
UoS12258 improved performance in three different cognition paradigms using a variety of 
approaches to cause impairments (i.e. delay, scopolamine and age).  
 
The NOR test was the most sensitive paradigm, particularly following sub-chronic dosing. 
UoS12258 reversed a delay-induced deficit in novel object recognition in rats after both acute 
dosing and sub-chronic dosing. However, behavioural studies in the water maze showed that 
although UoS12258 was effective at improving aged-induced deficits in learning and 
retention the MED, 3 mg/kg, was higher than in the NOR study. This difference could be a 
reflection of young and aged rats’ performance in particular cognitive tasks or it could be due 
to the underlying mechanisms involved in performing the task. NOR is dependent on the 
innate curiosity of the rat to explore novelty and might be more sensitive to modulation of 
AMPAR activity than in a model which involves the complex physiological processes which 
are altered during cognitive impairment associated with aging. Similarly the higher MED, 3 
mg/kg in the passive avoidance cognition model could reflect the increased difficulty in 
overcoming a scopolamine-induced impairment compared to a time-induced deficit used in 
the NOR model. 
Interestingly, a bell-shaped dose-response relationship (i.e., loss of, or reduced, effect at 
higher doses) was apparent in both the NOR and water maze paradigms. 
 
In addition to UoS12258 being an AMPAR positive modulator microdialysis studies have 
shown that it also enhances cholinergic neurotransmission in brain structures, the dorsal 
hippocampus and anterior cingulate cortex, which are implicated in cognitive functioning. 
 
4.4 Safety and tolerability 
Although UoS12258 decreased seizure threshold at doses greater than 10 mg/kg it should be 
noted brain concentrations in the MEST test were approximately 20 fold higher than 
concentrations measured after improved performance of NOR after acute dosing. Further 
research is ongoing to identify molecules that exhibit a greater margin between efficacious 
exposures and those which evoke pro-convulsant activity. 
  
 
 
5. Conclusions 
UoS12258 is a selective positive allosteric modulator of AMPA-type ionotropic glutamate 
receptors exhibiting equivalent potency at all AMPA receptor subtypes, with no measurable 
activity on other glutamate receptors. At comparable concentrations (10-15 nM), UoS12258 
has been shown to potentiate AMPA receptor currents in vitro; enhance synaptic AMPA 
receptor-mediated activity in vivo as well as demonstrating an excellent in vivo efficacy 
profile. 1 improved novel object recognition task performance in the rat at low brain 
concentrations which were consistent with its activity on native tissue in vitro, importantly 
efficacious concentrations were significantly lower than those required for efficacy with 
compounds such as CX516 in a similar assay (Damgaard 2010).  UoS12258 was also 
effective at improving rats’ performance of water maze and passive avoidance suggestive of 
enhanced learning and memory, although at higher concentrations. On the basis of the 
preclinical studies reported in this article, UoS12258 would be expected to be highly 
efficacious at improving cognitive measures in schizophrenic patients as well as other 
diseases with cognitive impairments, and is therefore a worthy candidate for clinical 
evaluation.  
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FIGURES & TABLES 
 
 
 
 
Figure 1. Concentration-response curve and chemical structure for UoS12258 showing its 
potentiation of glutamate-induced rises in intracellular calcium in HEK293 cells stably 
expressing the hGluA2i homomeric AMPAR, pEC50 = 5.57. Responses are normalised to 150 
µM cyclothiazide. Mean ± sem, n= 6 independent experiments. 
  
  
 
Figure 2. A, Representative whole cell current traces recorded from a single HEK293 cell 
expressing hGluA2i homomeric AMPARs. UoS12258 (1-100 µM, upper concentration limited 
by solubility) produced a concentration-dependent and reversible increase in charge transfer. 
Positive modulator, cyclothiazide 30 µM, also increased charge transfer following application 
of glutamate (line 7). B, Concentration-response curve for the potentiation of hGluA2i-
mediated inward currents by UoS12258, pEC50 = 5.19. Responses are normalized to 30 µM 
cyclothiazide. n= 4 independent experiments. 
  
  
 
 
  
Figure 3. Rat native neuronal data.  A, Concentration-response plot for UoS12258 -mediated 
potentiation of charge transfer. B, Concentration-response plot for UoS12258 -mediated 
potentiation of AMPAR deactivation. C, Concentration-response plot for the inhibition of 
AMPAR desensitisation induced by UoS12258.  Responses were normalised to 30 µM AMPA 
control. Lowest concentration to cause a significant (*P<0.05) difference.  
  
 
Figure 4. Representative traces recorded from the dentate gyrus of the anaesthetised rat 
following vehicle (left trace) and 0.1 mg/kg i.v. administration of UoS12258 (right trace). 
Synaptic traces are an average of 10 consecutive responses; the population spike is ringed in 
blue. 
  
  
 
Figure 5. A Effects of UoS12258 on NOR in rats after acute administration (0.1-1 mg/kg p.o., 
4 h prior to T1 and T2); B Effects of UoS12258 on NOR in rats after 7-days sub-chronic 
administration (0.003-0.03 mg/kg p.o. dosed daily for 7 days and then 4 h prior to T1 and 
T2). Significant differences (*P<0.05, **P<0.01) compared to vehicle treated animals. 
  
 
  
 
 
 
Figure 6. Effects of acute UoS12258 and SB-399885T on scopolamine-induced impairment of a PA 
response in adult Wistar rats. Data represent mean ± SEM avoidance latency at the 24 hour recall 
time. Significant difference (*p<0.05) compared to scopolamine-treated animals (Mann-Whitney u-
test, n = 6 per group). 
  
  
 
 
 
 
Figure 7. Effect of sub-chronic UoS12258 on acquisition of a water maze spatial learning task by 
aged Wistar rats. Data represents mean ± SEM escape latency (sec) averaged over the 5 trials of 
each training session. By session 3 there was a significant, P<0.05, difference between groups 
administered with either 3 mg/kg or 10 mg/kg compared to vehicle treated animals (n = 6 per 
group). 
  
  
 
 
 
 
Figure 8. Effect of sub-chronic UoS12258 on recall of a water maze spatial task by aged rats. Data 
represents mean ± SEM time (s) swimming in the target quadrant of the water maze during probe 
trials 1, 3 and 7 days post-training. Significant difference (*P<0.05) compared to vehicle treated 
animals. 
  
  
 
 
Figure 9.  Acetyl choline (ACh) and dopamine (DA) percent changes from basal (line graphs) 
and total efflux (bar chart - calculated as area under the curve (AUC) of percent changes 
from basal levels) in the anterior cingulate cortex (left panel) and dorsal hippocampus (right 
panel) following administration of UoS12258 (0.1, 0.3 and 1.0 mg/kg, p.o). Significant 
differences (*P<0.05 and **P<0.01) compared to vehicle treated animals.  
  
UoS12258 
(mg/kg) 
CC50 
(mA) 
+ sem % change 
compared 
to vehicle 
Mean Blood 
levels 
(ng/mL) 
Mean Brain 
levels 
(ng/g) 
Saline 58.5 3.4 - - - 
Picrotoxin 25.8 1.9 -56% *** - - 
1% MeCell 55.5 3.7 - - - 
10 50.0 4.9 -10% 1285 2283 
30 32.5 3.2 -41% *** 2136 3390 
100 23.5 2.1 -58% *** 2151 4961 
 
Table 1 (10, 30, 100 mg/kg, p.o., 2h ptt) in CD rats in the pro-convulsant MEST test. 
Significant difference (***P<0.001) compared to vehicle treated animals.  
